CD8A and COVID-19: Taken together, we propose that the COVID-19 mRNA vaccine likely mimics an antiviral innate inflammatory response that programs the robust differentiation of a heterogeneous pool of Type 1 effector CD8 T cells containing subsets that transition into long-lived memory T cells and display durable persistence in circulation, lymphoid tissues, and lung airways.